Therillia Development Company Inc. is an autonomous portfolio company of Sanderling Ventures located in Montreal. Its mandate is to cost effectively develop novel drug candidates of interest to Sanderling and other venture capital investors from preclinical to clinical proof of concept. Central to this mission is the deployment of scientific platforms to support the proof of concept strategies by identifying potential responder patient populations, rational drug combinations, and the utility of clinical biomarkers. By utilizing an experienced team of drug developers over multiple projects, Therillia will significantly reduce the time and cost of achieving proof of concept data for important new therapeutics. Ultimately, drug candidates successfully developed by Therillia will result in new sustainable biopharmaceutical companies in Quebec.